KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Income from Continuing Operations (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Income from Continuing Operations for 4 consecutive years, with 47151000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Income from Continuing Operations fell 57.73% year-over-year to 47151000.0, compared with a TTM value of 146398000.0 through Dec 2023, down 192.35%, and an annual FY2024 reading of 162857000.0, down 11.24% over the prior year.
  • Income from Continuing Operations was 47151000.0 for Q4 2023 at AbCellera Biologics, down from 28610000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 168573000.0 in Q1 2022 and bottomed at 47151000.0 in Q4 2023.
  • Average Income from Continuing Operations over 4 years is 20541312.5, with a median of 2508000.0 recorded in 2020.
  • Peak annual rise in Income from Continuing Operations hit 5700.62% in 2021, while the deepest fall reached 694.02% in 2021.
  • Year by year, Income from Continuing Operations stood at 161160000.0 in 2020, then crashed by 62.8% to 59948000.0 in 2021, then plummeted by 149.86% to 29893000.0 in 2022, then tumbled by 57.73% to 47151000.0 in 2023.
  • Business Quant data shows Income from Continuing Operations for ABCL at 47151000.0 in Q4 2023, 28610000.0 in Q3 2023, and 30527000.0 in Q2 2023.